Silicon Valley / San Jose Business Journal -- Articulinx Inc., a medical device company focusing on osteoarthritis, closed a second round of funding with $10 million. The Cupertino company said the funds will be used to continue development of its first produce, the Articulinx CMC Spacer, which is implanted through a small incision under local anesthesia and acts as a spacer to separate bones in joints where the articular cartilage has degenerated.
